From Wikipedia, the free encyclopedia

Carla Faith Bender Kim is a professor at the Department of Genetics at Harvard Medical School [1] and a Principal Investigator at the Stem Cell Program at Boston Children’s Hospital. [2] She is also a Principal Faculty member at the Harvard Stem Cell Institute, [3] where she also serves as part of the Executive Committee. [4]

Early life and education

Kim was born in Fremont, Ohio. Kim received her bachelor's degree from Ohio Northern University (1997) and a Ph.D. in Genetics from the University of Wisconsin-Madison (2002). Kim completed her postdoctoral training in the Tyler Jacks Laboratory at MIT (2006) [2] with the support of the Jane Coffin Childs Research Fellowship. [5]

During her time in the Jacks Lab, Kim discovered the first stem cell population in the adult mouse lung, bronchioalveolar stem cells (BASCs). [6]

Research

Working with genetically engineered mouse models that accurately represent human lung cancer, Kim’s group was the first to identify cancer stem cell populations in the two most frequent types of lung cancer in patients. [7] [8] Her lab’s knowledge in lung stem cells has revealed a new combination therapy approach for particular subsets of lung cancer patients. [9] Most recently, Kim’s lab has developed a 3D lung organoid system that makes it possible to derive specialized lung cells from lung stem cells. [10] Kim’s work has been recognized by a variety of organizations, she has received the Forbeck Scholar Award, [11] V Scholar award, [12] the Basil O’Connor Scholar award from the March of Dimes, [13] the American Cancer Society’s Research Scholar award, [14] and most recently the William Rippe Award for Distinguished Research in Lung Cancer from the Lung Cancer Research Foundation. [15] Kim’s work and lab are supported by federal funding from the National Institutes of Health. [16]

References

  1. ^ "Carla Bender Kim, Ph.D. | HMS Department of Genetics". genetics.med.harvard.edu. Retrieved 2016-08-02.
  2. ^ a b "The Kim Lab | Boston Children's Hospital". stemcell.childrenshospital.org. 18 March 2010. Retrieved 2016-08-02.
  3. ^ "Carla F. Kim, PhD". hsci.harvard.edu. Retrieved 2016-08-02.
  4. ^ "Leadership". Retrieved 2016-08-02.
  5. ^ "Carla Kim, PhD | Boston Children's Hospital". stemcell.childrenshospital.org. 18 March 2010. Retrieved 2016-08-02.
  6. ^ Kim, Carla F. Bender; Jackson, Erica L.; Woolfenden, Amber E.; Lawrence, Sharon; Babar, Imran; Vogel, Sinae; Crowley, Denise; Bronson, Roderick T.; Jacks, Tyler (2005-06-17). "Identification of bronchioalveolar stem cells in normal lung and lung cancer". Cell. 121 (6): 823–835. doi: 10.1016/j.cell.2005.03.032. ISSN  0092-8674. PMID  15960971.
  7. ^ Xu, Chunxiao; Fillmore, Christine M.; Koyama, Shohei; Wu, Hongbo; Zhao, Yanqiu; Chen, Zhao; Herter-Sprie, Grit S.; Akbay, Esra A.; Tchaicha, Jeremy H. (2014-05-12). "Loss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expression". Cancer Cell. 25 (5): 590–604. doi: 10.1016/j.ccr.2014.03.033. ISSN  1878-3686. PMC  4112370. PMID  24794706.
  8. ^ Curtis, Stephen J.; Sinkevicius, Kerstin W.; Li, Danan; Lau, Allison N.; Roach, Rebecca R.; Zamponi, Raffaella; Woolfenden, Amber E.; Kirsch, David G.; Wong, Kwok-Kin (2010-07-02). "Primary tumor genotype is an important determinant in identification of lung cancer propagating cells". Cell Stem Cell. 7 (1): 127–133. doi: 10.1016/j.stem.2010.05.021. ISSN  1875-9777. PMC  2908996. PMID  20621056.
  9. ^ Fillmore, Christine M.; Xu, Chunxiao; Desai, Pooja T.; Berry, Joanne M.; Rowbotham, Samuel P.; Lin, Yi-Jang; Zhang, Haikuo; Marquez, Victor E.; Hammerman, Peter S. (2015-04-09). "EZH2 inhibition sensitizes BRG1 and EGFR mutant lung tumours to TopoII inhibitors". Nature. 520 (7546): 239–242. Bibcode: 2015Natur.520..239F. doi: 10.1038/nature14122. ISSN  1476-4687. PMC  4393352. PMID  25629630.
  10. ^ Lee, Joo-Hyeon; Bhang, Dong Ha; Beede, Alexander; Huang, Tian Lian; Stripp, Barry R.; Bloch, Kenneth D.; Wagers, Amy J.; Tseng, Yu-Hua; Ryeom, Sandra (2014-01-30). "Lung stem cell differentiation in mice directed by endothelial cells via a BMP4-NFATc1-thrombospondin-1 axis". Cell. 156 (3): 440–455. doi: 10.1016/j.cell.2013.12.039. ISSN  1097-4172. PMC  3951122. PMID  24485453.
  11. ^ "2007 Scholar Retreat – Summary - William Guy Forbeck Research Foundation". 2007-01-30. Archived from the original on 2016-09-19. Retrieved 2016-08-02.
  12. ^ "Grants Awarded by State | The V Foundation for Cancer Research". www.jimmyv.org. Retrieved 2016-08-02.
  13. ^ "Speakers". Retrieved 2016-08-02.
  14. ^ "'Window of Vulnerability' | HMS". hms.harvard.edu. Retrieved 2016-08-02.
  15. ^ "Lung Cancer Research Foundation Awards $2.1 Million In Grants To Further Critical Research | News & Views". Lung Cancer Research Foundation. Retrieved 2016-08-02.
  16. ^ "Project Information - NIH RePORTER - NIH Research Portfolio Online Reporting Tools Expenditures and Results". projectreporter.nih.gov. Retrieved 2016-08-02.